Genedrive PLC Hardman Res: Hep-C point-of-care test launched
18 January 2018 - 10:59PM
RNS Non-Regulatory
TIDMGDR
Genedrive PLC
18 January 2018
Hardman Res: Hep-C point-of-care test launched
Hepatitis C point-of-care diagnostic launched - genedrive plc is
a commercial-stage company focused on point-of-care/need molecular
diagnostics and biomarkers. Its Genedrive(R) molecular diagnostic
testing platform is at the forefront of this technology, offering a
rapid, low-cost, simple-to-use device with high sensitivity and
specificity in infectious disease diagnosis. Rapid analysis of
patient samples greatly aids clinical and public health decision-
making, with field testing particularly important in emerging
markets. Hepatitis C diagnosis is a multi-million-dollar market
opportunity; the company launched its Genedrive HCV ID Kit in 1H'18
at the IFCC World Lab conference in South Africa.
Please click here for the full report:
http://hardmanandco.com/docs/default-source/company-docs/genedrive-plc-documents/18.01.18-hepatitis-c-point-of-care-diagnostic-launched.pdf
To contact us: Contacts: mh@hardmanandco.com
Hardman & Co Dr Martin dmh@hardmanandco.com
35 New Broad Street Hall gp@hardmanandco.com
London Dr Dorothea
EC2M 1NH Hill
www.hardmanandco.com Dr Gregoire
Follow us on Twitter Pave
@HardmanandCo
+44 20 7194
7622
About Hardman & Co: For the past 21 years Hardman has been
producing specialist research designed to improve investors'
understanding of companies, sectors, industries and investment
securities. Our analysts are highly experienced in their sectors,
and have often been highly rated by professional investors for
their knowledge. Our focus is to raise companies' profiles across
the UK and abroad with outstanding research, investor engagement
programmes and advisory services. Some of our notes have been
commissioned by the company which is the subject of the note; this
is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an
appointed representative of Capital Markets Strategy Ltd and is
authorised and regulated by the Financial Conduct Authority; our
FCA registration number is 600843. Hardman Research Ltd is
registered at Companies House with number 8256259.
Our research is provided for the use of the professional
investment community, market counterparties and sophisticated and
high net worth investors as defined in the rules of the regulatory
bodies. It is not intended to be made available to unsophisticated
retail investors. Anyone who is unsure of their categorisation
should consult their professional advisors. This research is
neither an offer, nor a solicitation, to buy or sell any security.
Please read the note for the full disclaimer.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEAFFPFSKPEFF
(END) Dow Jones Newswires
January 18, 2018 06:59 ET (11:59 GMT)
Epistem (LSE:EHP)
Historical Stock Chart
From Apr 2024 to May 2024
Epistem (LSE:EHP)
Historical Stock Chart
From May 2023 to May 2024